HIV infection and tobacco smoking behaviour: Prospects for prevention? ANRS CO3 Aquitaine Cohort, 2002

International Journal of Tuberculosis and Lung Disease

Volumn 10, Issue 4, 2006, Pages 378-383

  Bénard, Antoine ^a,b   Tessier, J F ^a   Rambeloarisoa, J ^b   Bonnet, F ^b,c   Fossoux, H ^b   Neau, D ^b   Dutronc, H ^b   Lazaro, E ^b,c   Dabis, F ^a,b   Chene G ^a  

^a INSERM   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

HIV AIDS; Prevalence estimate; Tobacco cessation; Tobacco smoking

Indexed keywords

ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; FEMALE; FRANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE;

EID: 33645683288     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Doll R, Peto R, Wheatley K, et al. Mortality in relation to smoking: 40 years' observations on male British doctors. Br Med J 1994; 309: 901-911.
2. Doll R, Peto R, Boreham J, et al. Mortality in relation to smoking: 50 years' observations on male British doctors. Br Med J 2004; 328: 1519-1527.
3. CASCADE Collaboration. Survival after introduction of HAART in people with known duration of HIV-1 infection. The CASCADE Collaboration. Concerted Action on SeroConversion to AIDS and Death in Europe. Lancet 2000; 355: 1158-1159.
4. Mocroft A, Vella S, Benfield T L, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352: 1725-1730.
5. Mocroft A, Ledergerber B, Katlama C, et al. EuroSIDA study group. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362: 22-29.
6. Bonnet F, Morlat P, Chene G, et al. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA). Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998-1999. HIV Med 2002; 3: 195-199.
7. Louie J K, Hsu L C, Osmond D H, et al. Trends in causes of death among persons with Acquired Immunodeficiency Syndrome in the era of Highly Active Antiretroviral Therapy, San Francisco, 1994-1998. J Infect Dis 1998; 186: 1023-1027.
8. Jain M K, Skiest D J, Cloud J W, et al. Changes in mortality related to human immunodeficiency virus infection: comparative analysis of inpatient deaths in 1995 and in 1999-2000. Clin Infect Dis 2003; 36: 1030-1038.
9. Lewden C, Salmon D, Morlat P, et al. Mortality 2000 study group. Causes of death among human immunodeficiency virus (HIV)-infected adults in the area of potent antiretroviral therapy: emerging role of hepatitis and cancer, persistent role of AIDS. Im J Epidemiol 2005; 34: 121-130.
10. Arcavi L, Benowitz N L. Cigarette smoking and infection. Arch Intern Med 2004; 164: 2206-2216.
11. Mercie P, Thiebaut R, Lavignolle V, et al. Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Ann Med 2002; 34: 55-63.
12. Saves M, Chene G, Ducimetiere P, et al. French WHO MONICA Project and the APROCO (ANRS EP11) Study Group. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003; 37: 292-298.
13. Thiebaut R, Morlat P, Jacqmin-Gadda H, et al. Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d'Epidemiologie du SIDA en Aquitaine (GECSA). AIDS 2000; 14: 971-978.
14. World Health Organization. Guidelines for controlling and monitoring the tobacco epidemic. Geneva; Switzerland: WHO, 1998.
15. Beck F, Legleye S, Peretti-Watel P. Penser les drogues : représentation des produits et opinions sur les politiques publiques EROPP 2002, rapport OFDT, 2003, 226 p. www.ofdt.fr/BDD/publications/docs/ epfxfbj1.pdf Asscessed February 2006.
16. Beck F, Legleye S. Adults and drugs: levels of use and recent trends. Trends 2003; 30: 1-11. www.drogues.gouv.fr/uk/professionnal/pdf/tend30.pdf Accessed January 2006.
17. Baromètre santé 2000. Volume 1. Méthode. Guilbert P, Baudier F, Gautier A, Goubert A C, Arwidson P, Janvrin M P: 144 p. Volume 2.
18. Résultats. Guilbert P, Baudier F, Gautier A (sous la dir.). Vanves, France: INPES, 2001 : 480 p www.inpes. sante.fr/Barometres/Baro2000/pdf/ tabac.pdf Accessed January 2006
19. Niaura R, Shadel W G, Morrow K, et al. Smoking among HIV-positive persons. Ann Behav Med 1999; 21 (Suppl): S116.
20. Mamary E M, Bahrs D, Martinez S. Cigarette smoking and the desire to quit among individuals living with HIV. AIDS Patient Care STDS 2002; 16: 39-42.
21. Arday D R, Edlin B R, Giovino G A, et al. Smoking, HIV infection, and gay men in the United States. Tobacco Control 1993; 2: 156-158.
22. Friis-Moller N, Weber R, Reiss P, et al. DAD study group. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17: 1179-1193.
23. Chandola T, Head J, Bartley M. Socio-demographic predictors of quitting smoking: how important are household factors? Addiction 2004; 99: 770-777.
24. Curry S, Thompson B, Sexton M, Omenn G S. Psychosocial predictors of outcome in a worksite smoking cessation program. Am J Prev Med 1989; 5: 2-7.
25. Levy D T, Romano E, Mumford E. The relationship of smoking cessation to sociodemographic characteristics, smoking intensity, and tobacco control policies. Nicotine Tob Res 2005; 7: 387-396.